Cancer Research Technology
Log in Register
Menu

CDK inhibitor BS-194 Small Molecule (Tool Compound)

Invented at Imperial College

Info

Catalogue Number 153191
Type Inhibitor
Relevance BS-194 is a selective and potent CDK inhibitor, which inhibits CDK2, CDK1, CDK5, CDK7, and CDK9.
On Target IC50 CDK2, CDK1, CDK5, CDK7, and CDK9 (IC50=3, 30, 30, 250, and 90 nmol/L, respectively)
Selectivity CDK1, CDK2, CDK7, and CDK9
Molecular Formula C20H27N5O3
lUPAC (2S,3S)-3-(7-(benzylamino)-3- isopropylpyrazolo[1,5-a]pyrimidin-5- ylamino)butane-1,2,4-triol
Molecular Weight (g/mol) 385.5
Research Area Cancer, Cell Cycle
Storage Ambient

References

There are 2 reference entries for this reagent.

View All References

References: 2 entries

Heathcote et al. 2010. J Med Chem. 53(24):8508-22. PMID: 21080703.

A novel pyrazolo[1,5-a]pyrimidine is a potent inhibitor of cyclin-dependent protein kinases 1, 2, and 9, which demonstrates antitumor effects in human tumor xenografts following oral administration.

Europe PMC ID: 21080703


Add a reference

References: 2 entries

Heathcote et al. 2010. J Med Chem. 53(24):8508-22. PMID: 21080703.

A novel pyrazolo[1,5-a]pyrimidine is a potent inhibitor of cyclin-dependent protein kinases 1, 2, and 9, which demonstrates antitumor effects in human tumor xenografts following oral administration.


Add a reference

Inventor Information

No inventors are currently linked to this reagent.

Add an inventor